Robert Luo Managing Partner of HM Capital

Mr. Luo founded HM Capital in 2018. He has over 25 years of professional experience in investment, entrepreneurship, operations and management, life sciences research, and clinical practice.

Mr. Luo founded Huimei Healthcare Management Services (HM HMS) in 2015 and has served as CEO. He then created several operating entities, such as HM Technology and HM Health under HM HMS, and has served as chairman. At the same time, he invested in several companies and provided post-investment value-add services, including WeDoctor, Hisun-Pfizer Pharmaceutical, Gaoji Medical, Genor Biopharma, etc.

Prior to founding HM HMS, Mr. Luo was a senior investment officer at Mayo Clinic and led multi-billion dollar investments globally, including Asia-Pacific, and invested in dozens of well-known global investment firms and healthcare companies. Earlier, Mr. Luo worked on neural stem cell research for 5 years at the Neurobiotechnology Center at the Ohio State University and completed his ophthalmology residency training at Peking Union Hospital in Beijing.

Mr. Luo received his MBA from the Ohio State University and Bachelor in Medicine from Peking University Health Science Center.

Wanning Xu Partner and Chief Operating Officer of HM Capital

Dr. Xu joined HM Capital in 2019 and is the head of fund operations and management, focusing on fund establishment and fundraising, IR, PR and GR management, fund finance, risk control, research and systematic construction, as well as portfolio monitoring and exiting management.

With 20 years of experience in investment and investment banking, Dr. Xu has held key positions at CITIC Group, China Galaxy Securities, Morgan Stanley and other institutions. She also served as a securities consultant at Beijing Municipal Bureau of Finance Affairs, financial consultant of China Investment Corporation's overseas investment branch, and member of the expert panel of China Securities Association’s Qualify Examination.

Dr. Xu led the Qihoo 360 privatization investment, Neptunus refinancing and other projects, with a cumulative investment amount of over RMB 1 billion. She has a deep understanding of domestic and overseas multi-level capital markets, medical and healthcare industry research, and capital management.

Dr. Xu received her doctorate of Economics from Graduate School of Chinese Academy of Social Sciences.

Dongcheng (Peter) Lu Venture Partner of HM Capital

Dr. Lu has more than three-decade of experience in investment, academic research and clinical practice in China, the United States and Israel. Dr. Lu joined HM Capital as a venture partner in 2022.

Dr. Lu was the Founding and Managing Partner of New Vision Ventures (NVV). Prior to that, Dr. Lu served as a Partner for Israel Infinity Group and an Executive Director for Toucan Capital (USA). Dr. Lu has been focusing on life science sector that encompasses biotech, medtech and healthcare-related cutting-edge technology.

Dr. Lu was a senior research scientist at Yale School of Medicine and participated in translational research on therapeutic antibody drugs and anti-virus vaccine. In addition, Dr. Lu practiced cardiology in China for years.

Dr. Lu received his MBA from Yale School of Management (SOM) and Ph.D. from Peking University.

Successful Case: WEIGO, United Imaging, Haoyun Bang, Orange Family, Dakang Medicine, Leads Bio-labs, ZD Medical, Life Perfusor Medical, Huatai Pharma, Given Image, Enspectra Health, Northwest Biotherapeutics.

Yi Guo Chief Scientific Officer of HM Capital

Dr. Guo has more than 20 years of biological research experience. She joined HM Capital in 2022 as the Chief Scientific Officer, mainly responsible for conducting scientific research review of the potential investment companies and deal sourcing of biotech and medtech companies in the United States.

Prior to joining HM Capital, Dr. Guo served as an assistant professor at Mayo Clinic for ten years, guiding independent laboratories to engage in scientific research on fat metabolism, fatty acid lipotoxicity and liver cancer. Previously, Dr. Guo worked as a postdoctoral researcher at University of California, San Francisco. Her representative works were published in Nature, Cell Metabolism and other peer reviewed top scientific research journals.

Dr. Guo received her Ph.D. in biochemistry from Brandeis University and B.S. in biochemistry and molecular biology from Peking University.